发明名称 |
Method of treating pulmonary disorders with liposomal amikacin formulations |
摘要 |
Disclosed herein are methods of treating pulmonary disorders comprising administering to the patient an effective dose of a nebulized liposomal amikacin formulation for at least one treatment cycle, wherein: the treatment cycle comprises an administration period of 15 to 75 days, followed by an off period of 15 to 75 days; and the effective dose comprises 100 to 2500 mg of amikacin daily during the administration period. |
申请公布号 |
US9119783(B2) |
申请公布日期 |
2015.09.01 |
申请号 |
US201213480246 |
申请日期 |
2012.05.24 |
申请人 |
Insmed Incorporated |
发明人 |
Gupta Renu |
分类号 |
A61K9/127;A61K31/7036;A61K9/00;A61K31/375;A61K31/70 |
主分类号 |
A61K9/127 |
代理机构 |
Cooley LLP |
代理人 |
Cooley LLP |
主权项 |
1. A method of treating a Pseudomonas aeruginosa infection in a human patient comprising administering to the patient an effective dose of a nebulized liposomal amikacin formulation for at least one treatment cycle, wherein:
the lipid component of the liposomal amikacin formulation comprises dipalmitoylphosphatidylcholine (DPPC) and a sterol, the at least one treatment cycle comprises an administration period of 20 to 35 days, followed by an off period of 15 to 75 days;during which an improvement in lung function is maintained for at least 15 days after the administration period ends,
wherein the improvement in lung function comprises an increase in Forced Expiratory Volume in one second (FEV1), an increase in blood oxygen saturation, or both, as compared to the human patient prior to the at least one treatment cycle or an untreated human patient suffering from a Pseudomonas aeruginosa infection; and the effective dose comprises 510 mg to 610 mg of amikacin daily during the administration period. |
地址 |
Bridgewater NJ US |